Get the Stockscreener App
1.815
0.81%
0.015
Accuray Inc stock is traded at $1.815, with a volume of 276.80K.
It is up +0.81% in the last 24 hours and down -5.00% over the past month.
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
See More
Previous Close:
$1.80
Open:
$1.78
24h Volume:
276.80K
Relative Volume:
0.32
Market Cap:
$180.49M
Revenue:
$447.48M
Net Income/Loss:
$-14.55M
P/E Ratio:
-18.15
EPS:
-0.1
Net Cash Flow:
$7.61M
1W Performance:
-2.45%
1M Performance:
-5.00%
6M Performance:
+12.01%
1Y Performance:
-35.20%
1-Day Range:
$1.77
$1.86
1-Week Range:
$1.73
$1.90
52-Week Range:
$1.40
$3.05
Accuray Inc Stock (ARAY) Company Profile
Name
Accuray Inc
Sector
Industry
Phone
608-824-2800
Address
1240 DEMING WAY, MADISON, CA
Accuray Inc Stock (ARAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Loop Capital | Buy |
| Jan-21-20 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-01-18 | Upgrade | Citigroup | Sell → Neutral |
| Dec-13-17 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-30-17 | Initiated | Lake Street | Buy |
| Dec-14-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-22-15 | Initiated | RBC Capital Mkts | Sector Perform |
| Nov-12-15 | Initiated | Citigroup | Sell |
| May-01-15 | Reiterated | Dougherty & Company | Buy |
| Jan-12-15 | Initiated | Northland Capital | Outperform |
| Jan-31-14 | Reiterated | Dougherty & Company | Buy |
| Jan-29-14 | Reiterated | Brean Capital | Buy |
| Nov-11-13 | Reiterated | Dougherty & Company | Buy |
| Aug-29-13 | Reiterated | Dougherty & Company | Buy |
| Sep-20-11 | Reiterated | Ticonderoga | Buy |
| Feb-08-10 | Upgrade | Jefferies & Co | Hold → Buy |
| Dec-09-09 | Upgrade | UBS | Sell → Neutral |
| Mar-09-09 | Downgrade | Soleil | Buy → Hold |
| Jan-30-09 | Upgrade | Piper Jaffray | Neutral → Buy |
| Dec-22-08 | Reiterated | Jefferies & Co | Hold |
| Aug-20-08 | Reiterated | Jefferies & Co | Hold |
View All
Accuray Inc Stock (ARAY) Latest News
Accuray (NASDAQ:ARAY) Shares Cross Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Brain Cancer Treatment Industry Set to Flourish Key Regions - openPR
Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024 - StockTitan
Accuray Appoints Michael Murphy as VP Corporate Controller - TipRanks
Accuray Appoints Michael Murphy as VP, Corporate Controller - StockTitan
Comparing enVVeno Medical (NASDAQ:NVNO) and Accuray (NASDAQ:ARAY) - Defense World
Here's Why You Should Retain Accuray Stock in Your Portfolio Now - MSN
New England Journal of Medicine Study Reaffirms Five Session Radiation Treatment Provides Comparable Rates of Cancer Control, Tolerability and Sexual Functioning to Conventional Radiotherapy Treatment in Men with Localized Prostate Cancer - PR Newswire
Philippines Radiotherapy Market to See Booming Growth - openPR
Financial Metrics Unveiled: Accuray Inc (ARAY)’s Key Ratios in the Spotlight - The Dwinnex
Lung Cancer Surgery Market: Detailed Analysis Of Growth Factors - openPR
Accuray CEO Suzanne Winter resumes role after leave By Investing.com - Investing.com Canada
Accuray CEO Returns from Medical Leave - MarketWatch
Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence - PR Newswire
Orthopedic Surgical Robot Market is Projected to Reach a Valuation of US$ 8.34 Billion at a CAGR of 13.5% by 2034 | Fact.MR Report - GlobeNewswire Inc.
Radiotherapy Device Market is Likely to Upsurge at USD 25.16 Bn- Varian Medical Systems, Elekta AB, Accuray, Inc., C.R. Bard, Inc., IBA – IndiaPolitics.com - IndiaPolitics.com
Here's Why You Should Retain Accuray (ARAY) Stock for Now - MSN
Radiotherapy Device Market is Likely to Upsurge at USD 25.16 Bn- Varian Medical Systems, Elekta AB, Accuray, Inc., C.R. Bard, Inc., IBA – KnowCasino - KnowCasino
Dimensional Fund Advisors LP Cuts Stock Position in Accuray Incorporated (NASDAQ:ARAY) - Defense World
Dimensional Fund Advisors LP Has $2.46 Million Holdings in Accuray Incorporated (NASDAQ:ARAY) - MarketBeat
Accuray Inc [NASDAQ: ARAY] Sees Increase in Stock Value - Knox Daily
What is Accuray Inc (ARAY) Stock Return on Shareholders’ Capital? - SETE News
Medical Robot Market Gain Momentum with Major Giants Medtronic, Stryker, Accuray, Omnicell - EIN News
Ablation Technology Market Growth Report | Accuray, Biosense, Corporation, Webster, Smith & Nephew, Varian Medical Systems, Olympus Corporation – Times-BD24 - Times-BD24
Accuray Inc (ARAY) shows promising results - US Post News
Accuray Inc (ARAY) receives a Buy rating from ROTH MKM - Knox Daily
Intelligent Automation in Healthcare Industry Growing Massively – Siemens, General Electric, Accuray - Elektrotransports.lv
AI-based Surgical Robots Market 2024 Global Future Forecasts | Accuray Incorporated, Hansen Medical, Intuitive Surgical, Inc. – Cauverynews - Cauverynews
A closer look at Accuray Inc (ARAY) is warranted - US Post News
Accuray Inc [ARAY] Records 50-Day SMA of $1.9142 - Knox Daily
It is Poised to be a Bull Market for Accuray Inc (ARAY) - SETE News
Accuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife® S7™ System Medical Professional Training - PR Newswire
500,000 Shares in Accuray Incorporated (NASDAQ:ARAY) Bought by Armistice Capital LLC - Defense World
Armistice Capital LLC Makes New $910,000 Investment in Accuray Incorporated (NASDAQ:ARAY) - MarketBeat
Is Accuray Inc (ARAY) worth investing in despite its overvalued state? - US Post News
Accuray rolls out Helix to boost cancer treatment in India - The Hindu
Non-Melanoma Skin Cancer Market Research Insights With - openPR
Selling Buzz: Accuray Inc [ARAY] SVP Chief Financial Officer Pervaiz Ali sells 8,404 shares of the company - Knox Daily
Research Analysts’ Price Target Changes for September 18th (ACN, AGF.B, ANIP, ANP, APA, AZPN, BDC, BKR, BLDR, BNTX) - Defense World
Accolade CFO sells over $500 worth of shares to cover tax obligations - Investing.com
A History of Outperforming Analyst Forecasts and Beating the Odds: Accuray Inc (ARAY) - SETE News
Accuray Inc Inc. (ARAY) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Stock Surge: Accuray Inc (ARAY) Closes at 1.90, Marking a -12.84 Increase/Decrease - The Dwinnex
Catalist-listed Serial Achieva forges new IT JV with A-Speed Infotech - Singapore Business Review
Abdiel Capital Advisors LP buys $668k in Appian Corp stock - Investing.com
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan - MSN
(ACNT) Trading Signals - Stock Traders Daily
ARAY (Accuray Inc) has impressive results - US Post News
Market Watch: Aclarion Inc (ACON)’s Noteworthy Drop, Closing at 0.18 - The Dwinnex
Accuray Launches Advanced Radiotherapy Solution, Aims To Bridge Cancer Care Gaps - BW Healthcare
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Analysts - MarketBeat
Accuray Inc Stock (ARAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Accuray Inc Stock (ARAY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chalke Sandeep | SVP, Chief Commercial Officer |
Dec 01 '23 |
Sale |
1.70 |
26,799 |
45,612 |
531,341 |
| Pervaiz Ali | SVP Chief Financial Officer |
Jun 04 '24 |
Sale |
1.70 |
2,701 |
4,597 |
402,542 |
| WHITTERS JOSEPH E | Director |
May 29 '24 |
Buy |
1.58 |
50,000 |
79,000 |
561,053 |
| WHITTERS JOSEPH E | Director |
May 28 '24 |
Buy |
1.54 |
50,000 |
77,045 |
511,053 |
| Hoge Michael | Senior VP Global Operations |
Mar 01 '24 |
Sale |
2.59 |
11,991 |
31,057 |
390,208 |
| Pervaiz Ali | SVP Chief Financial Officer |
Jan 03 '24 |
Sale |
2.74 |
2,116 |
5,800 |
402,743 |
| Corradetti GIna | VP, CAO and Controller |
Jan 03 '24 |
Sale |
2.74 |
14,129 |
38,729 |
196,138 |
| Spine Patrick | SVP, Chief Admin Officer |
Dec 01 '23 |
Sale |
2.47 |
14,832 |
36,653 |
219,484 |
| Winter Suzanne C | President |
Dec 01 '23 |
Sale |
2.47 |
65,390 |
161,624 |
1,369,811 |
| Pervaiz Ali | SVP Chief Financial Officer |
Dec 01 '23 |
Sale |
2.47 |
13,463 |
33,271 |
404,859 |
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):